0001415889-24-020106.txt : 20240725 0001415889-24-020106.hdr.sgml : 20240725 20240725163239 ACCESSION NUMBER: 0001415889-24-020106 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240723 FILED AS OF DATE: 20240725 DATE AS OF CHANGE: 20240725 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ragosa Mark CENTRAL INDEX KEY: 0001835458 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38492 FILM NUMBER: 241142503 MAIL ADDRESS: STREET 1: C/O KINIKSA PHARMACEUTICALS CORP. STREET 2: 100 HAYDEN AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Kiniksa Pharmaceuticals International, plc CENTRAL INDEX KEY: 0001730430 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 23 OLD BOND STREET, FLOOR 3 CITY: LONDON STATE: X0 ZIP: WIS 4PZ BUSINESS PHONE: 7814319100 MAIL ADDRESS: STREET 1: 23 OLD BOND STREET, FLOOR 3 CITY: LONDON STATE: X0 ZIP: WIS 4PZ FORMER COMPANY: FORMER CONFORMED NAME: Kiniksa Pharmaceuticals, Ltd. DATE OF NAME CHANGE: 20180205 4 1 form4-07252024_080736.xml X0508 4 2024-07-23 0001730430 Kiniksa Pharmaceuticals International, plc KNSA 0001835458 Ragosa Mark 23 OLD BOND STREET, THIRD FLOOR LONDON X0 W1S 4PZ UNITED KINGDOM false true false false CHIEF FINANCIAL OFFICER 1 Class A Ordinary Share 2024-07-23 4 M 0 24248 11.10 A 43501 D Class A Ordinary Share 2024-07-23 4 S 0 24248 24.79 D 19253 D Share Option 11.10 2024-07-23 4 M 0 24248 0 D 2032-04-06 Class A Ordinary Share 24248 40412 D This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on August 22, 2023. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $24.72 and $25.095. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 7, 2022. /s/ Madelyn Zeylikman, Attorney-in-Fact 2024-07-25